ArticleCancer medicine2023

Cost-effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China.

Zhe Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.